Edoxaban Monotherapy in Nonvalvular Atrial Fibrillation Patients with Coronary Artery Disease

Edoxaban Monotherapy in Nonvalvular Atrial Fibrillation Patients with Coronary Artery Disease

Background. Current guidelines recommend an oral anticoagulant (OAC) monotherapy in patients with nonvalvular atrial fibrillation (NVAF) and stable coronary artery disease (CAD) 1 year postpercutaneous coronary intervention (PCI). It might be possible to shorten the time for de-escalation from a dua...

Full description

Bibliographic Details
Main Authors:	Daisuke Fukamachi, Yasuo Okumura, Naoya Matsumoto, Eizo Tachibana, Koji Oiwa, Makoto Ichikawa, Hironori Haruta, Kazumiki Nomoto, Ken Arima, Atsushi Hirayama
Format:	Article
Language:	English
Published:	Hindawi-Wiley 2022-01-01
Series:	Journal of Interventional Cardiology
Online Access:	http://dx.doi.org/10.1155/2022/5905022

Similar Items

Editorial to the Postmarketing surveillance on the clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF Japan): One‐year safety and effectiveness analyses
by: Koichi Nagashima, et al.
Published: (2020-06-01)

Low alanine aminotransferase levels are independently associated with mortality risk in patients with atrial fibrillation
by: Yuki Saito, et al.
Published: (2022-07-01)

Current use of direct oral anticoagulants for atrial fibrillation in Japan: Findings from the SAKURA AF Registry
by: Yasuo Okumura, et al.
Published: (2017-08-01)

Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US
by: Miller JD, et al.
Published: (2016-05-01)

Massive left atrial calcification
by: Masaki Monden, et al.
Published: (2023-02-01)

ST‐elevation myocardial infarction after COVID‐19 infection in a young man with Kawasaki disease
by: Yuro Matsunaga, et al.
Published: (2022-11-01)

Effectiveness and safety of edoxaban versus warfarin in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies
by: Mohammed M. Alsultan, et al.
Published: (2023-11-01)

Laboratory Test Predictors for Major Bleeding in Elderly (≥80 Years) Patients With Nonvalvular Atrial Fibrillation Treated With Edoxaban 15 mg: Sub‐Analysis of the ELDERCARE‐AF Trial
by: Takeshi Mikami, et al.
Published: (2022-09-01)

Postmarketing surveillance on clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF‐Japan): Three‐month interim analysis results
by: Takeshi Yamashita, et al.
Published: (2019-02-01)

Postmarketing surveillance on the clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF‐Japan): One‐year safety and effectiveness analyses
by: Takeshi Yamashita, et al.
Published: (2020-06-01)

Safety and effectiveness of edoxaban in Japanese patients with nonvalvular atrial fibrillation: Final report of a two‐year postmarketing surveillance study (ETNA‐AF‐Japan)
by: Takeshi Yamashita, et al.
Published: (2021-04-01)

The edoxaban‐M4 metabolite and measurement of edoxaban by chromogenic assays in human plasma
by: Romain Siriez, et al.
Published: (2022-03-01)

Postmarketing safety experience with edoxaban in Japan for thromboprophylaxis following major orthopedic surgery
by: Kuroda Y, et al.
Published: (2013-10-01)

Systematic review and network meta-analysis of the relative efficacy and safety of edoxaban versus other nonvitamin K antagonist oral anticoagulants among patients with nonvalvular atrial fibrillation and CHADS score ⩾ 2
by: Maria M Fernandez, et al.
Published: (2015-11-01)

Unsolved issues of The Efficacy and Safety of Edoxaban
by: Leszek Drabik, et al.
Published: (2021-06-01)

Asymptomatic left ventricular pseudoaneurysm
by: Taisuke Hanamura, et al.
Published: (2024-03-01)

The Edoxaban Hokusai VTE PEDIATRICS Study: An open‐label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease
by: Cornelia Heleen vanOmmen, et al.
Published: (2020-07-01)

Rapid Assay for the Therapeutic Drug Monitoring of Edoxaban
by: Md Abdur Rashid, et al.
Published: (2022-04-01)

Edoxaban in venous thromboembolism and stroke prevention: an appraisal
by: Proietti M, et al.
Published: (2016-02-01)

Impact of Edoxaban on Thrombin-Dependent Platelet Aggregation
by: Juraj Sokol MD, PhD, et al.
Published: (2020-10-01)

The Spatial Distribution of Plaque Vulnerabilities in Patients with Acute Myocardial Infarction.
by: Guian Zheng, et al.
Published: (2016-01-01)

Treatment of pulmonary thromboembolism with edoxaban in a cancer patient with borderline fulfillment of the dose reduction criteria
by: Takuro Takama, et al.
Published: (2019-09-01)

Risk impact of edoxaban in the management of stroke and venous thromboembolism
by: Hurst KV, et al.
Published: (2016-08-01)

Sensory evaluation of edoxaban orally disintegrating tablets: an open-label interventional study (secondary publication)
by: Takeshi Yamashita, et al.
Published: (2019-02-01)

A case of typical atrial flutter causing unexpected advanced atrioventricular block despite lateral cavotricuspid isthmus ablation
by: Hiroaki Mano, et al.
Published: (2012-10-01)

Factors associated with bleeding events during catheter ablation with uninterrupted periprocedural edoxaban for atrial fibrillation: a subanalysis of the KYU-RABLE study
by: Ichitaro Abe, et al.
Published: (2021-08-01)

Factor Xa inhibitor, edoxaban ameliorates renal injury after subtotal nephrectomy by reducing epithelial‐mesenchymal transition and inflammatory response
by: Lixin Fang, et al.
Published: (2022-03-01)

The role of edoxaban in preventing thromboembolic complications in patients with atrial fibrillation
by: O. O. Shakhmatova
Published: (2020-12-01)

Edoxaban-related Spontaneous Renal Hematoma: A Case Report
by: Ayberk Iplikci, et al.
Published: (2020-10-01)

Comparative risk impact of edoxaban in the management of stroke and venous thromboembolism
by: Tellor KB, et al.
Published: (2016-04-01)

Edoxaban Dosing Time Affects Blood Coagulation Inhibition in Rats
by: Naoto Nagata, et al.
Published: (2021-04-01)

Automated Thrombin Generation Assay for Rivaroxaban, Apixaban, and Edoxaban Measurements
by: Tamana Meihandoest, et al.
Published: (2021-09-01)

Factors Associated With Edoxaban Concentration Among Patients With Atrial Fibrillation
by: Shin-Yi Lin, et al.
Published: (2021-09-01)

Feasibility of edoxaban for asymptomatic cancer-associated thrombosis in Japanese patients with gastrointestinal cancer: ExCAVE study
by: Michio Nakamura, et al.
Published: (2022-12-01)

Changes in plasma concentrations of edoxaban and coagulation biomarkers according to thromboembolic risk and atrial fibrillation type in patients undergoing catheter ablation: Subanalysis of KYU‐RABLE
by: Tetsuji Shinohara, et al.
Published: (2021-02-01)

Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe)
by: Raffaele De Caterina, et al.
Published: (2019-07-01)

Safety and efficacy of uninterrupted treatment with edoxaban or warfarin during the peri‐procedural period of catheter ablation for atrial fibrillation
by: Kazuya Naito, et al.
Published: (2020-08-01)

Antithrombotic Therapy According to the Guidelines Issued by the Japanese Circulation Society in Patients with Nonvalvular Paroxysmal Atrial Fibrillation without Thromboembolic Risk Factors
by: Mahito Ozawa, MD, et al.
Published: (2009-01-01)

Prediction and Implications of Edoxaban-Associated Bleeding in Patients after Critical Illness
by: Ryusei Mikami, et al.
Published: (2023-01-01)

Risk management in patients with atrial fibrillation and comorbid conditions: potentialities of edoxaban
by: O. L. Barbarash, et al.
Published: (2020-11-01)